PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend

<p>Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee says</p><ul><li><p>Get our <a href="https://www.theguardian.com/email-newsletters?CMP=cvau_sfl">breaking news email</a>, <a href="https://app.adjust.com/w4u7jx3">free app</a> or <a href="https://www.theguardian.com/australia-news/series/full-story?CMP=cvau_sfl">daily news podcast</a></p></li></ul><p>The federal government should fund treatment for thousands of women with breast cancer or endometriosis, and children with gender dysphoria, according to the Pharmaceutical Benefits Scheme’s advisory committee.</p><p>The committee met urgently in July in response to AstraZeneca’s announcement it would remove Zoladex from the market, risking leaving more than 7,500 women with breast cancer without an alternative treatment.</p> <a href="https://www.theguardian.com/australia-news/2026/aug/18/pbs-breast-cancer-endometriosis-gender-dysphoria-puberty-blocker-drug-triptorelin-ntwnfb">Continue reading...</a>